OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF POST-STROKE EPILEPSY
Keywords:
post-stroke epilepsy, antiepileptic drugs, hemorrhagic stroke, ischemic strokeAbstract
Post-stroke epilepsy today is one of the important and serious complications of acute cerebrovascular accident, which significantly aggravates the post-stroke condition. Post-stroke epilepsy ranks third in the frequency of neurological problems in the elderly and ranges from 32.4% to 52.3% according to multicenter studies conducted in the USA and France. Stroke-related attacks are not uniform in nature. It is known that each subsequent epileptic seizure (EP) is associated with vital risk and worsening the prognosis of the course and control of epilepsy (Kwan P., Brodie M.J., 2000), especially in an elderly patient with a stroke.
References
Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Coté R, et al.. Seizures after stroke: a prospective multicenter study. Arch Neurol. (2000) 57:1617–22. 10.1001/archneur.57.11.1617
Xu M.Y. Poststroke seizure: optimizing its management. Stroke Vasc Neurol. 2018; 4 (1): 48-56. https://doi.org/10.1136/SVN-2018-000175.
Ischemic stroke and transient ischemic attack in adults. Clinical recommendations. 2021. URL: https://cr.minzdrav.gov.ru/recomend/171_2 (access date 02/15/2023).
Fisher R.S., Cross J.H., D'Souza C., et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsy. 2017; 58 (4): 531-42. https://doi.org/10.1111/epi.13671.
U. A. M. Al-Sakhli, L. M. Tibekina, O. P. Subbotina, V. V. Flood Post-stroke epileptic seizures: risk factors, clinical picture, principles of diagnosis and treatment. Journal of Epilepsy and Paroxysmal Conditions Vol. 15, No. 2 (2023
Barolin G.S., Sherzer E. EpileptischeAnfallebeiApoplektikern. Wein Nervenh 1962;20:35–47.
Holtkamp M, Beghi E, Benninger F, Kälviäinen R, Rocamora R, Christensen H. European Stroke Organization guidelines for the treatment of post-stroke seizures and epilepsy. European Journal of Stroke. 2017; 2 (2): 103–115. doi: 10.1177/2396987317705536. [
Qian C, Löppönen P, Tetri S, Huhtakangas J, Juvela S, Turtiainen HME, Bode MK, Hillbom M. Immediate, early and late onset after primary intracerebral hemorrhage. Epilepsy research. 2014; 108(4):732–739. doi: 10.1016/j.eplepsyres.2014.02.020.
Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, Deruyter F, Eng JJ, Fisher B, Harvey RL, Lang CE, MacKay-Lyons M, Ottenbacher KJ, Pugh S, Reeves MJ, Richards L .G., Stiers V., Zorowitz R.D. Guide to rehabilitation and recovery after stroke in adults. 2016; 47: e98–e169. doi: 10.1161/STR.0000000000000098.
Zöllner JP, Konczalla J, Stein M, Roth C, Krakow K, Kaps M, Steinmetz H, Rosenow F, Misselwitz B, Strzelczyk A. Acute symptomatic seizures in intracerebral and subarachnoid hemorrhage: a population-based study of 19,331 patients. Epilepsy research. 2020; 161:106286. doi: 10.1016/j.eplepsyres.2020.106286.
Lahti A.M., Saloheimo P., Huhtakangas J., Salminen H., Juvela S., Bode M.K., Hillbom M., Tetri S. Post-stroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology. 2017; 88(23):2169–2175. doi: 10.1212/WNL.
Lopponen P, et al. Predictive value of C-reactive protein for the outcome after primary intracerebral hemorrhage. Journal of Neurosurgery. 2014;121:1374–1379. doi: 10.3171/2014.7.JNS132678.
Price M, Gunther A, Kwan JS. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database of Systematic Reviews. 2016 doi: 10.1002/14651858.CD005501.pub4.
Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA. Recommendation for a definition of acute symptomatic seizure. Epilepsy. 2010;51(4):671–675. doi: 10.1111/j.1528-1167.2009.02285.x
Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Archives of Neurology. 2002;59(2):195–201. doi: 10.1001/archneur.59.2.195.
Redfors P, Holmegaard L, Pedersen A, Jern C, Malmgren K. Long-term follow-up of post-stroke epilepsy after ischemic stroke: Room for improved epilepsytreatment. Seizure. 2020;76:50–55. doi: 10.1016/j.seizure.2020.01.009
Trinka E, Marson AG, van Paesschen W, Kälviäinen R, Marovac J, Duncan B, Buyle S, Hallström Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B. KOMET: An unblinded , randomized, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Journal of Neurology, Neurosurgery and Psychiatry. 2013;84(10):1138–1147. doi: 10.1136/jnnp-2011-300376.
Gilad R, Sadeh M, Rapoport A, Dabby R, Boaz M, Lampl Y. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clinical Neuropharmacology. 2007;30(4):189–195. doi: 10.1097/WNF.0b013e3180333069.
French JA, Perucca E, Sander JW, Bergfeldt L, Baulac M, Auerbach Ds, Keezer M, Thijs RD, Devinsky O, Vossler DG, Welty TE. FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsy Open. 2021;6(1):45–48. doi: 10.1002/epi4.12475.
Belcastro V, Costa C, Galletti F, Autuori A, Pierguidi L, Pisani F, Calabresi P, Parnetti L. Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. Epilepsy Research. 2008;82(2-3):223–226. doi: 10.1016/j.eplepsyres.2008.08.008]
Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain & Development. 2011;33(4):289–293. doi: 10.1016/j.braindev.2010.06.008.
Consoli D, et al. Levetiracetam versus carbamazepine in patients with late poststroke seizures: A multicenter prospective randomized open-label study (epicproject) Cerebrovascular Diseases. 2012;34:282–289. doi: 10.1159/000342669
Rosenow F, Brandt C, Bozorg A, Dimova S, Steiniger-Brach B, Zhang Y, Ferrò B, Holmes GL, Kälviäinen R. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurologica Scandinavica. 2020;141(6):473–482. doi: 10.1111/ane.13230.
Belcastro V, Vidale S, Pierguidi L, Sironi L, Tancredi L, Striano P, Taborelli A, Arnaboldi M. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: A proof-of-concept, observational study. Seizure. 2013;22(10):905–907. doi: 10.1016/j.seizure.2013.07.011.
35. Fleet JL, Dixon SN, Kuwornu PJ, Dev VK, Montero-Odasso M, Burneo J, Garg AX. Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. PLOS ONE. 2018;13(3):e0193134. doi: 10.1371/journal.pone.0193134.
Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert‐Schmitz M, Kniess T, Schmitz B, Bernedo V, Ruckes C, Ehrlich A, Krämer G. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsy. 2015;56(3):450–459. doi: 10.1111/epi.12926.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S , Maguire M, Mohanraj M, Jauhari P. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomized controlled trial. Lancet. 2021;397(10282):1363–1374. doi: 10.1016/S0140-6736(21)00247-6.
Alvarez-Sabín J, Montaner J, Padró L, Molina CA, Rovira R, Codina A, Quintana M. Gabapentin in late-onset poststroke seizures. Neurology. 2002;59(12):1991–1993. doi: 10.1212/01.wnl.0000038388.57824.b6.
Sales F, Chaves J, McMurray R, Loureiro R, Fernandes H, Villanueva V. Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli. Acta Neurologica Scandinavica. 2020;142(6):563–573. doi: 10.1111/ane.13323.
Mazzocchetti P, Mancini M, Sciaccaluga M, Megaro A, Bellingacci L, di Filippo M, Cesarini EN, Romoli M, Carrano N, Gardoni F, Tozzi A, Calabresi P, Costa M. Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiology of Diseases. 2020;140:104848. doi: 10.1016/j.nbd.2020.104848.
